BioAge Labs, Inc. (BIOA)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $858.79M
- P/E ratio
- —
- EPS
- —
- Volume
- 321,329
- 52-week high
- —
- 52-week low
- —
- Open
- $22.85
- Day high
- $23.53
- Day low
- $22.29
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $9M | -$80.61M | -$2.24 |
| 2024 | $0 | -$71.11M | -$6.63 |
| 2023 | — | -$63.85M | -$38.17 |
About BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
- CEO
- Kristen Fortney
- Employees
- 62
- Country
- US
- IPO date
- Sep 26, 2024
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is BioAge Labs, Inc.'s stock price today?
- BIOA is trading at $22.32 as of Jul 20, 2026.
- What is BioAge Labs, Inc.'s market cap?
- BioAge Labs, Inc. (BIOA) has a market capitalization of $858.79M.
- Does BioAge Labs, Inc. pay a dividend?
- BioAge Labs, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is BioAge Labs, Inc. in?
- BioAge Labs, Inc. operates in the Healthcare sector.